Sunshine Biopharma (SBFM) Net Income towards Common Stockholders Growth (3y) (2015 - 2026)
Sunshine Biopharma (SBFM) Net Income towards Common Stockholders Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn | -20.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.13% |
| Mar 31, 2026 | 9.93% |
| Dec 31, 2025 | 55.01% |
| Sep 30, 2025 | 30.12% |
| Jun 30, 2025 | -76.26% |
| Mar 31, 2025 | 1.55% |
| Dec 31, 2024 | -73.64% |
| Sep 30, 2024 | 33.32% |
| Jun 30, 2024 | 14.84% |
| Mar 31, 2024 | 40.79% |
| Dec 31, 2022 | -249.06% |
| Jun 30, 2022 | -627.65% |
| Mar 31, 2022 | -736.51% |
| Dec 31, 2021 | 285.93% |
| Sep 30, 2021 | -815.50% |
| Jun 30, 2021 | -711.24% |
| Mar 31, 2021 | -194.50% |
| Dec 31, 2019 | 54.66% |
| Jun 30, 2019 | 26.05% |
| Mar 31, 2019 | 69.79% |